Sinovac Biotech Ltd.
SVA · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $644 | $644 | $644 | $644 |
| - Cash | $1,072 | $1,270 | $1,643 | $4,278 |
| + Debt | $325 | $299 | $263 | $75 |
| Enterprise Value | -$103 | -$327 | -$736 | -$3,560 |
| Revenue | – | $308 | $140 | $280 |
| % Growth | – | 119.3% | -49.9% | – |
| Gross Profit | – | $308 | -$48 | -$150 |
| % Margin | – | 100% | -34.2% | -53.3% |
| EBITDA | – | -$27 | $21 | -$1,000 |
| % Margin | – | -8.7% | 14.8% | -356.4% |
| Net Income | – | -$117 | $17 | -$371 |
| % Margin | – | -38% | 12% | -132.2% |
| EPS Diluted | – | -1.17 | 0.15 | -3.73 |
| % Growth | – | -880% | 104% | – |
| Operating Cash Flow | – | $146 | -$40 | $152 |
| Capital Expenditures | – | -$53 | -$93 | -$150 |
| Free Cash Flow | – | $93 | -$133 | $2 |